lamotrigine has been researched along with MS (Multiple Sclerosis) in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this phase 2 trial, we aimed to assess whether the sodium-channel blocker lamotrigine is also neuroprotective in patients with secondary progressive multiple sclerosis." | 9.14 | Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. ( Altmann, DR; Brenner, R; Chataway, J; Furby, J; Hayton, T; Hughes, RA; Kapoor, R; Miller, DH; Smith, KJ, 2010) |
| " The 2 treatment periods began with an 8-week, double-blind titration period, during which the number of pills of study drug was increased until either total pain relief was achieved, 1 or more unmanageable adverse events were reported, or a maximum of 16 pills (400 mg of lamotrigine) were used daily." | 9.12 | A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. ( Breuer, B; Guleyupoglu, N; Knotkova, H; Pappagallo, M; Portenoy, RK; Wallenstein, S, 2007) |
| " In this phase 2 trial, we aimed to assess whether the sodium-channel blocker lamotrigine is also neuroprotective in patients with secondary progressive multiple sclerosis." | 5.14 | Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. ( Altmann, DR; Brenner, R; Chataway, J; Furby, J; Hayton, T; Hughes, RA; Kapoor, R; Miller, DH; Smith, KJ, 2010) |
| " The 2 treatment periods began with an 8-week, double-blind titration period, during which the number of pills of study drug was increased until either total pain relief was achieved, 1 or more unmanageable adverse events were reported, or a maximum of 16 pills (400 mg of lamotrigine) were used daily." | 5.12 | A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. ( Breuer, B; Guleyupoglu, N; Knotkova, H; Pappagallo, M; Portenoy, RK; Wallenstein, S, 2007) |
| "Lamotrigine displayed the lowest risk of discontinuation when prescribed as initial monotherapy for epilepsy in MS." | 4.02 | Retention of antiseizure medications for epilepsy in multiple sclerosis: A retrospective observational study. ( Burman, J; Håkansson, S; Mahamud, Z; Zelano, J, 2021) |
| "Treatment with lamotrigine was associated with more rashes (20% vs 5%, P value 0." | 2.52 | Sodium channel blockers for neuroprotection in multiple sclerosis. ( Hao, Z; Wen, J; Yang, C; Zeng, L; Zhang, L, 2015) |
| "Lamotrigine trial in SPMS was a randomised control trial to assess whether partial blockade of sodium channels has a neuroprotective effect." | 1.39 | Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression. ( Brenner, R; Furby, J; Giovannoni, G; Gnanapavan, S; Grant, D; Hayton, T; Kapoor, R; Leoni, V; Marta, M; Miller, DH; Morant, S; Palace, J; Teunissen, CE, 2013) |
| "Carbamazepine (CBZ) was prescribed in 36 patients, with adverse effects reported in 20 cases, of which 12 mimicked a relapse." | 1.33 | Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. ( Battaglia, MA; Brichetto, G; Mancardi, GL; Messmer Uccelli, M; Solaro, C, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Browne, L | 1 |
| Lidster, K | 1 |
| Al-Izki, S | 1 |
| Clutterbuck, L | 1 |
| Posada, C | 1 |
| Chan, AW | 1 |
| Riddall, D | 1 |
| Garthwaite, J | 1 |
| Baker, D | 1 |
| Selwood, DL | 1 |
| Mahamud, Z | 1 |
| Håkansson, S | 1 |
| Burman, J | 1 |
| Zelano, J | 1 |
| Gnanapavan, S | 1 |
| Grant, D | 1 |
| Morant, S | 1 |
| Furby, J | 2 |
| Hayton, T | 2 |
| Teunissen, CE | 1 |
| Leoni, V | 1 |
| Marta, M | 1 |
| Brenner, R | 2 |
| Palace, J | 1 |
| Miller, DH | 2 |
| Kapoor, R | 4 |
| Giovannoni, G | 1 |
| Yang, C | 1 |
| Hao, Z | 1 |
| Zhang, L | 1 |
| Zeng, L | 1 |
| Wen, J | 1 |
| Smith, KJ | 2 |
| Altmann, DR | 1 |
| Chataway, J | 1 |
| Hughes, RA | 1 |
| Bermel, RA | 1 |
| Cohen, JA | 1 |
| Valentino, P | 1 |
| Nisticò, R | 1 |
| Pirritano, D | 1 |
| Bilotti, G | 1 |
| Del Giudice, F | 1 |
| Sturniolo, M | 1 |
| Quattrone, A | 1 |
| Bittner, S | 1 |
| Höhn, K | 1 |
| Göbel, K | 1 |
| Kleinschnitz, C | 1 |
| Wiendl, H | 1 |
| Meuth, SG | 1 |
| Solaro, C | 3 |
| Brichetto, G | 1 |
| Battaglia, MA | 1 |
| Messmer Uccelli, M | 1 |
| Mancardi, GL | 3 |
| Reiss, JP | 1 |
| Sam, D | 1 |
| Sareen, J | 1 |
| Bechtold, DA | 1 |
| Miller, SJ | 1 |
| Dawson, AC | 1 |
| Sun, Y | 1 |
| Berry, D | 1 |
| Breuer, B | 1 |
| Pappagallo, M | 1 |
| Knotkova, H | 1 |
| Guleyupoglu, N | 1 |
| Wallenstein, S | 1 |
| Portenoy, RK | 1 |
| McCleane, G | 1 |
| Uccelli, MM | 1 |
| Cianchetti, C | 1 |
| Zuddas, A | 1 |
| Randazzo, AP | 1 |
| Perra, L | 1 |
| Marrosu, MG | 1 |
| Leandri, M | 1 |
| Lundardi, G | 1 |
| Inglese, M | 1 |
| Messmer-Uccelli, M | 1 |
| Gottlieb, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial[NCT02104661] | Phase 2 | 30 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis: Single Centre, Phase 2 Trial[NCT00257855] | Phase 2 | 120 participants | Interventional | 2005-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for lamotrigine and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Sodium channel blockers for neuroprotection in multiple sclerosis.
Topics: Disease Progression; Female; Humans; Immunosuppressive Agents; Lamotrigine; Male; Middle Aged; Multi | 2015 |
[Pregabalin and gabapentin in multiple sclerosis: clinical experiences and therapeutic implications].
Topics: Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Antineoplastic Agents; Carbamazepine; Cohor | 2011 |
Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine.
Topics: Animals; Humans; Lamotrigine; Multiple Sclerosis; Neuroprotective Agents; Sodium Channel Blockers; T | 2008 |
3 trials available for lamotrigine and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Topics: Adolescent; Adult; Brain Infarction; Disability Evaluation; Disease Progression; Double-Blind Method | 2010 |
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Topics: Adolescent; Adult; Brain Infarction; Disability Evaluation; Disease Progression; Double-Blind Method | 2010 |
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Topics: Adolescent; Adult; Brain Infarction; Disability Evaluation; Disease Progression; Double-Blind Method | 2010 |
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Topics: Adolescent; Adult; Brain Infarction; Disability Evaluation; Disease Progression; Double-Blind Method | 2010 |
A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis.
Topics: Anticonvulsants; Cross-Over Studies; Double-Blind Method; Female; Humans; Lamotrigine; Male; Middle | 2007 |
Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis.
Topics: Analgesics; Analgesics, Non-Narcotic; Carbamazepine; Female; Humans; Lamotrigine; Male; Middle Aged; | 2000 |
11 other studies available for lamotrigine and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis.
Topics: Animals; Disease Models, Animal; Female; Humans; Imidazoles; Lymph Nodes; Male; Mice; Mice, Inbred C | 2014 |
Retention of antiseizure medications for epilepsy in multiple sclerosis: A retrospective observational study.
Topics: Anticonvulsants; Epilepsy; Humans; Lamotrigine; Multiple Sclerosis; Sweden | 2021 |
Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression.
Topics: Atrophy; Biomarkers; Brain; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; | 2013 |
Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options.
Topics: Adjuvants, Immunologic; Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humani | 2011 |
Lamotrigine therapy for paroxysmal dysarthria caused by multiple sclerosis: a case report.
Topics: Adult; Anticonvulsants; Ataxia; Dysarthria; Female; Humans; Lamotrigine; Magnetic Resonance Imaging; | 2011 |
Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study.
Topics: Adult; Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Follow-Up Studies; | 2005 |
Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delusions; Excitatory Amino Acid Antagonists; Female; | 2006 |
Axonal protection achieved in a model of multiple sclerosis using lamotrigine.
Topics: Action Potentials; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Lamotrigine; M | 2006 |
Lamotrigine can reduce neurogenic pain associated with multiple sclerosis.
Topics: Adult; Analgesics; Female; Humans; Lamotrigine; Multiple Sclerosis; Pain; Triazines | 1998 |
A patient with multiple sclerosis and Down's syndrome with a rare paroxysmal symptom at onset.
Topics: Acetates; Amines; Brain; Cyclohexanecarboxylic Acids; Down Syndrome; Excitatory Amino Acid Antagonis | 1999 |
Lamotrigine adjunctive therapy in painful phenomena in MS: preliminary observations.
Topics: Analgesics; Female; Humans; Lamotrigine; Male; Multiple Sclerosis; Pain; Triazines | 1999 |